Pfizer is in advanced talks to acquire U.S. cancer drug company Medivation for close to $14 billion, as it seeks to boost its oncology portfolio, people familiar with the matter said on Sunday.
Pfizer has agreed to pay a little more than $80 per share for Medivation, one of the people said, a substantial premium to the $52.50 offer for Medivation that France's Sanofi SA made in April, which eventually resulted in the company putting itself up for sale. Medivation shares ended trading in Ne...
18:21 Mark Zuckerberg takes the stand in $2 billion lawsuit claiming Oculus theft7
16:16 Luxottica, Essilor $24 billion merger creates eyewear giant17
05:02 Ringling Bros. and Barnum & Bailey Circus to close after 146 years14
23:23 Don’s what? Portable toilet names covered for inauguration16